Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.
Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.
Disc's light sensitivity drug succeeded in a test Monday, but a large placebo response confounded the results. The biotech stock plummeted.